Nevro (NVRO) Delivers 5th Consecutive Earnings Beat; Leerink Partners Raises Price Target to $68
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Nevro Reports Third Quarter 2015 Financial Results
November 9, 2015 4:01 PM ESTREDWOOD CITY, Calif., Nov. 9, 2015 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three and nine months ended September 30, 2015.
Third Quarter Highlights:
Achieved revenue of $15.4 million in the third quarter of 2015, an increase of 78% as reported, over the same period of the prior year U.S. revenue of $4.5 million for the third quarter of 2015, the first full quarter of commercial availability... More